Treatment
Immunoglobulins clinical trials
We’re tracking 79 recruiting studies that include Immunoglobulins, each written for real people, not researchers, below.
Recruiting studies
- NCT07375758RecruitingPhase 1/Phase 2
Testing MIL116 in healthy people and those with IgA Nephropathy
This study tests a new drug called MIL116 for IgA Nephropathy. First, healthy volunteers will test the drug's safety, then people with IgA Nephropathy will see if it can help reduce protein in their urine.
BeijingAges 18 years+ - NCT02735707RecruitingPhase 3
Adaptive trial for severe pneumonia care in intensive care
This study tests ways to improve treatment for adults with severe pneumonia that lands them in the ICU, adjusting the plan as results come in. It may help your care team find better treatments for lung infection and breathing/heart support needs.
Jacksonville, FloridaAges 18 years+ - NCT07182227RecruitingPhase 1/Phase 2
Gene therapy PS-002 for IgA nephropathy
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy. It aims to see if the treatment is safe and can help reduce protein loss in urine and protect kidney function.
Miami, FloridaAges 18 years+ - NCT07509151RecruitingPhase 3
Surovatamig after first treatment for CLL or SLL
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
AdelaideAges 18–18 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07149454Enrolling by invitationPhase 1
Testing a new antibody to prevent tetanus
This trial tests a new medicine made from antibodies that target tetanus toxin. It may help protect people from tetanus without needing a vaccine.
Lanzhou, GansuAges 18–60 - NCT05350774Enrolling by invitationPhase 2
IV immunotherapy for lingering neurologic effects after COVID-19
This Phase 2 trial tests whether intravenous immunotherapy (IVIG) can improve ongoing neurologic symptoms after a mild-to-moderate COVID-19 illness. It targets people with persistent symptoms such as brain fog, fatigue, trouble thinking, dizziness when standing, and balance or other neurologic problems.
Bethesda, MarylandAges 18–100
Common questions
- Are there clinical trials studying Immunoglobulins?
- Yes. Clin2 currently lists 79 recruiting studies that include Immunoglobulins, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Immunoglobulins trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Immunoglobulins an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Immunoglobulins or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.